Skip to main content

In Print: Last Week's Microarray Papers of Note: Jun 4, 2013


DNA methylation profiling of placental villi from karyotypically normal miscarriage and recurrent miscarriage.
Am J Pathol. 2013 Jun;182(6):2276-84.
Hanna C, McFadden D, Robinson W

Hypothesizing that aberrant DNA methylation may cause karyotypically normal miscarriage, the authors assessed DNA methylation in first-trimester chorionic villi in chromosomally normal miscarriages from women with recurrent miscarriage, isolated miscarriageand elective terminations using the Illumina Infinium HumanMethylation27 BeadChip array. They determined that altered DNA methylation in the placenta at specific loci, and global dysregulation in specific cases, may contribute to or be a consequence of poor placental function in karyotypically normal miscarriage.

Functional performance of aCGH design for clinical cytogenetics.
Comput Biol Med. 2013 Jul 1;43(6):775-85.
Gambin T, Stankiewicz P, Sykulski M, et al.

The authors of this paper propose a new approach to measure the quality of array CGH designs that measures the robustness of rearrangements detection to the noise. To accomplish this, they implemented the Monte Carlo method for testing noise robustness within DNAcopy software analysis procedure. This framework has been used to assess the functional quality of several array designs.

Gene copy number variations in breast cancer of Sub-Saharan African women.
Breast. 2013 Jun;22(3):295-300.
Ly M, Valent A, Diallo G, et al.

The authors carried out array comparative genomic hybridization profiling of breast cancer samples from Malian women and compared them with samples from American women. Six chromosomal regions were identified with a significant higher rate of copy number alterations. They concluded that breast cancers from African women contain biological differences with those occurring in the US.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.